Kiniksa Pharmaceuticals International (KNSA) Receivables - Net (2021 - 2025)
Kiniksa Pharmaceuticals International's Receivables - Net history spans 5 years, with the latest figure at $15.6 million for Q4 2025.
- For Q4 2025, Receivables - Net fell 62.63% year-over-year to $15.6 million; the TTM value through Dec 2025 reached $15.6 million, down 62.63%, while the annual FY2025 figure was $15.6 million, 62.63% down from the prior year.
- Receivables - Net reached $15.6 million in Q4 2025 per KNSA's latest filing, down from $51.7 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $51.7 million in Q3 2025 to a low of $2.6 million in Q2 2021.
- Average Receivables - Net over 5 years is $19.5 million, with a median of $16.0 million recorded in 2024.
- Peak YoY movement for Receivables - Net: crashed 74.78% in 2023, then surged 718.41% in 2024.
- A 5-year view of Receivables - Net shows it stood at $4.0 million in 2021, then soared by 217.69% to $12.7 million in 2022, then skyrocketed by 67.98% to $21.3 million in 2023, then surged by 96.2% to $41.7 million in 2024, then tumbled by 62.63% to $15.6 million in 2025.
- Per Business Quant, the three most recent readings for KNSA's Receivables - Net are $15.6 million (Q4 2025), $51.7 million (Q3 2025), and $31.9 million (Q2 2025).